Cytokinetics, Incorporated (CYTK)

NASDAQ: CYTK · IEX Real-Time Price · USD
43.41
+0.58 (1.35%)
Feb 2, 2023, 9:37 AM EST - Market open
1.35%
Market Cap 4.10B
Revenue (ttm) 148.23M
Net Income (ttm) -282.15M
Shares Out 94.63M
EPS (ttm) -3.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,596
Open 42.40
Previous Close 42.83
Day's Range 43.18 - 43.61
52-Week Range 30.27 - 55.80
Beta 0.95
Analysts Buy
Price Target 63.31 (+45.84%)
Earnings Date Feb 23, 2023

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase II... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2004
Employees 253
Stock Exchange NASDAQ
Ticker Symbol CYTK
Full Company Profile

Financial Performance

In 2021, Cytokinetics's revenue was $70.43 million, an increase of 26.15% compared to the previous year's $55.83 million. Losses were -$215.31 million, 69.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 21 analysts, the average rating for CYTK stock is "Buy." The 12-month stock price forecast is $63.31, which is an increase of 45.84% from the latest price.

Price Target
$63.31
(45.84% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2023 it granted stock options to purchase an aggregate of 8...

17 hours ago - GlobeNewsWire

Cytokinetics Announces Recipients of Its Fifth Annual Communications Grant Program

Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communicat...

3 days ago - GlobeNewsWire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 30, 2022 it granted stock options to purchase an aggregate of ...

1 month ago - GlobeNewsWire

Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to pre...

1 month ago - GlobeNewsWire

Cytokinetics (CYTK) Up Despite Unfavorable FDA Committee Voting

Cytokinetics (CYTK) gets an unfavorable recommendation from CRDAC on omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction.

1 month ago - Zacks Investment Research

Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil

PDUFA Target Action Date is February 28, 2023

1 month ago - GlobeNewsWire

Cytokinetics Stock Trading Halted Today

FDA Advisory Committee to Review the New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure with Reduced Ejection Fraction FDA Advisory Committee to Review the New Drug Applica...

1 month ago - GlobeNewsWire

Cytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbil

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) posted briefing documents for th...

1 month ago - GlobeNewsWire

Cytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MND

Analysis from FORTITUDE-ALS Shows Predicted Survival Risk Score  Strongly Correlated with Decline in ALSFRS-R

2 months ago - GlobeNewsWire

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136

Advancement of Novel Cardiac Troponin Activator Expands Cardiovascular Franchise for Conditions Associated with Impaired Cardiac Contractility Advancement of Novel Cardiac Troponin Activator Expands C...

2 months ago - GlobeNewsWire

Cytokinetics Announces Presentation at the Virtual 33rd International Symposium on ALS/MND

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one poster presentation at the Virtual 33r d International Symposium on ALS/MND...

2 months ago - GlobeNewsWire

Cytokinetics Presents New Data at the American Heart Association Scientific Sessions 2022

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from two additional analyses from GALACTIC-HF (Global Approach to Lowe...

3 months ago - GlobeNewsWire

Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -7.56% and 11.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Cytokinetics Reports Third Quarter 2022 Financial Results

Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil on December 13, 2022;  PDUFA Target Action Date Set for February 28, 2023

3 months ago - GlobeNewsWire

Cytokinetics Announces Three Upcoming Presentations at the American Heart Association Scientific Sessions 2022

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming poster presentations at the American Heart Association Scientifi...

3 months ago - GlobeNewsWire

Cytokinetics to Announce Third Quarter Results on November 3, 2022

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 3, 2022 at 4:0...

3 months ago - GlobeNewsWire

Is Cytokinetics (CYTK) Outperforming Other Medical Stocks This Year?

Here is how Cytokinetics (CYTK) and Humana (HUM) have performed compared to their sector so far this year.

3 months ago - Zacks Investment Research

Cytokinetics (CYTK) to Continue ALS Study on Reldesemtiv

Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.

4 months ago - Zacks Investment Research

Cytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis

Phase 3 Clinical Trial to Proceed to Second Interim Analysis Expected to Occur in 2023 Phase 3 Clinical Trial to Proceed to Second Interim Analysis Expected to Occur in 2023

4 months ago - GlobeNewsWire

Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting

Treatment with Aficamten Associated with Significant Improvements in Symptoms and Quality of Life

4 months ago - GlobeNewsWire

Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions

New Analysis Demonstrates Successful Reduction or Withdrawal of Standard of Care Therapies in Patients Treated with Aficamten New Analysis Demonstrates Successful Reduction or Withdrawal of Standard o...

4 months ago - GlobeNewsWire

Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases

4 months ago - GlobeNewsWire

Cytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions and the HFSA Annual Scientific Meeting

Two Late Breaking Clinical Trials Sessions to Feature New Data from REDWOOD-HCM OLE Two Late Breaking Clinical Trials Sessions to Feature New Data from REDWOOD-HCM OLE

4 months ago - GlobeNewsWire

Life sciences is undervalued right now, says JMP Securities Mark Lehmann

JMP Securities CEO Mark Lehmann joins 'Closing Bell: Overtime' to discuss why he likes health care stocks as the place to be right now.

Other symbols: CFLTKRTXXBI
4 months ago - CNBC Television

Cytokinetics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor confere...

5 months ago - GlobeNewsWire